S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20

Selecta Biosciences Stock Forecast, Price & News

-0.28 (-8.81%)
(As of 11/26/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.38 million shs
Average Volume
1.25 million shs
Market Capitalization
$338.28 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Selecta Biosciences logo

About Selecta Biosciences

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. It produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm's proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.


Selecta's Gene Therapy Trial For Genetic Metabolic Disorder Put On FDA Hold
November 26, 2021 |  markets.businessinsider.com
Selecta Biosciences' (SELB) "Buy" Rating Reiterated at HC Wainwright
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$16.60 million
Book Value
($0.16) per share


Net Income
$-68.88 million
Pretax Margin




Free Float
Market Cap
$338.28 million

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.36 out of 5 stars

Medical Sector

221st out of 1,391 stocks

Pharmaceutical Preparations Industry

92nd out of 669 stocks

Analyst Opinion: 3.5Community Rank: 4.1Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.0 5 -4 -3 -2 -1 -

Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

Is Selecta Biosciences a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Selecta Biosciences stock.
View analyst ratings for Selecta Biosciences
or view top-rated stocks.

How has Selecta Biosciences' stock been impacted by COVID-19?

Selecta Biosciences' stock was trading at $3.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SELB shares have decreased by 6.1% and is now trading at $2.90.
View which stocks have been most impacted by COVID-19

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Selecta Biosciences

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences, Inc. (NASDAQ:SELB) announced its earnings results on Monday, November, 8th. The company reported ($0.16) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.07) by $0.09. During the same quarter last year, the firm posted ($0.09) earnings per share.
View Selecta Biosciences' earnings history

What price target have analysts set for SELB?

7 Wall Street analysts have issued 1-year price objectives for Selecta Biosciences' shares. Their forecasts range from $3.50 to $13.00. On average, they anticipate Selecta Biosciences' stock price to reach $7.92 in the next year. This suggests a possible upside of 173.0% from the stock's current price.
View analysts' price targets for Selecta Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the following people:

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD).

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (6.05%), Geode Capital Management LLC (1.50%), Two Sigma Advisers LP (1.30%), Goldman Sachs Group Inc. (1.13%), Two Sigma Investments LP (1.07%) and Deutsche Bank AG (0.52%). Company insiders that own Selecta Biosciences stock include Carsten Brunn, Lloyd P Johnston, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe.
View institutional ownership trends for Selecta Biosciences

Which major investors are selling Selecta Biosciences stock?

SELB stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Millennium Management LLC, SG Americas Securities LLC, Two Sigma Investments LP, Goldman Sachs Group Inc., Renaissance Technologies LLC, Two Sigma Advisers LP, and Russell Investments Group Ltd.. Company insiders that have sold Selecta Biosciences company stock in the last year include Carsten Brunn, Lloyd P Johnston, and Peter G Traber.
View insider buying and selling activity for Selecta Biosciences
or view top insider-selling stocks.

Which major investors are buying Selecta Biosciences stock?

SELB stock was purchased by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, BlackRock Inc., Connor Clark & Lunn Investment Management Ltd., Arrowstreet Capital Limited Partnership, Rafferty Asset Management LLC, UBS Group AG, Geode Capital Management LLC, and Opaleye Management Inc.. Company insiders that have bought Selecta Biosciences stock in the last two years include Peter G Traber, Timothy A Springer, and Timothy C Barabe.
View insider buying and selling activity for Selecta Biosciences
or or view top insider-buying stocks.

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $2.90.

How much money does Selecta Biosciences make?

Selecta Biosciences has a market capitalization of $338.28 million and generates $16.60 million in revenue each year. The company earns $-68.88 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Selecta Biosciences have?

Selecta Biosciences employs 44 workers across the globe.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is selectabio.com.

Where are Selecta Biosciences' headquarters?

Selecta Biosciences is headquartered at 65 Grove Street, Watertown MA, 02472.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 65 Grove Street, Watertown MA, 02472. The company can be reached via phone at (617) 923-1400, via email at [email protected], or via fax at 617-924-3454.

This page was last updated on 11/29/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.